大博医疗(002901) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was ¥217,501,203.83, representing a 40.31% increase compared to ¥155,016,817.70 in the same period last year[9] - Net profit attributable to shareholders for Q1 2019 was ¥82,700,447.72, up 20.58% from ¥68,587,021.72 year-on-year[9] - The net profit after deducting non-recurring gains and losses was ¥73,832,663.91, reflecting a 20.63% increase from ¥61,204,298.71 in the previous year[9] - Basic earnings per share for Q1 2019 were ¥0.210, a rise of 23.53% from ¥0.17 in the previous year[9] - The total comprehensive income for the period was ¥85,954,070.48, compared to ¥69,988,028.05 in the previous year, marking a significant increase[63] - The net profit for the current period is 92,163,500.01, an increase from 66,849,341.86 in the previous period, representing a growth of approximately 38.1%[70] - The total comprehensive income for the current period is 92,163,500.01, compared to 66,849,341.86 in the previous period, indicating a year-over-year increase of about 38.1%[70] Cash Flow - The net cash flow from operating activities was ¥32,733,896.57, an increase of 26.28% compared to ¥25,921,605.08 in the same period last year[9] - The company reported a significant increase in cash flow from operating activities, with cash received related to operating activities rising by ¥3,831,099.04, or 68.83%, from ¥5,565,979.34 to ¥9,397,078.38[27] - Cash inflow from operating activities totaled 213,900,427.60, compared to 163,186,184.62 in the previous period, marking an increase of around 30.9%[74] - Cash outflow from operating activities was 181,166,531.03, compared to 137,264,579.54 in the previous period, which is an increase of approximately 32.0%[74] - The cash flow from investing activities resulted in a net outflow of -65,916,020.60, compared to -49,350,476.49 in the previous period, indicating a decline in cash flow from investments[76] - The cash and cash equivalents at the end of the period amounted to 36,137,812.54, down from 187,984,615.81 in the previous period, showing a decrease of approximately 80.8%[76] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,754,292,704.07, which is a 5.36% increase from ¥1,665,064,091.68 at the end of the previous year[9] - Total current assets increased to ¥1,393,266,528.98 as of March 31, 2019, compared to ¥1,331,721,503.81 in the previous period, reflecting a growth of approximately 4.8%[40] - Total liabilities decreased slightly to ¥201,431,528.00 from ¥207,221,175.94, a reduction of about 2.7%[43] - Total liabilities decreased to ¥157,180,843.71 from ¥217,142,204.46, representing a reduction of 27.7%[56] - The total assets and equity ratio improved, with total assets at ¥1,669,012,493.22, up from ¥1,627,355,476.11[56] - The company’s financial position reflects stability with no significant changes in asset and liability values[94] Shareholder Information - Net assets attributable to shareholders increased by 6.37% to ¥1,531,573,611.51 from ¥1,439,889,332.18 at the end of the previous year[9] - The total number of ordinary shareholders at the end of the reporting period was 15,857[13] - Owner's equity increased to ¥1,552,861,176.07 from ¥1,457,842,915.74, reflecting a growth of approximately 6.5%[46] - The company's equity attributable to shareholders was approximately $1.44 billion[87] Expenses - Research and development expenses rose by ¥4,560,769.37, or 33.38%, from ¥13,662,822.20 to ¥18,223,591.57, attributed to an increase in R&D personnel and enhanced investment in new product development[24] - Sales expenses surged by ¥34,272,492.65, or 165.03%, from ¥20,766,966.28 to ¥55,039,458.93, driven by increased efforts in academic promotion and sales terminal development[24] - The company incurred a total of 49,218,502.85 in taxes paid, compared to 44,328,337.83 in the previous period, reflecting an increase of approximately 11.5%[74] Investment Activities - The company reported a decrease in cash received from investment activities, totaling ¥361,050,000.00, down 48.63% from ¥702,801,506.85, mainly due to the redemption of bank wealth management products[27] - The total amount of cash paid for the purchase of fixed assets increased by ¥31,955,691.67, or 313.77%, from ¥10,184,450.85 to ¥42,140,142.52, reflecting expanded production capacity[27] - The company received cash from investment recovery totaling 361,050,000.00, down from 702,801,506.85 in the previous period, indicating a decrease of about 48.7%[76] Future Outlook - The company plans to expand its market presence and invest in new product development to drive future growth[62]